DESTINY-CRC02: antibody-drug conjugates in colorectal cancer

(1:30)

S1 Episode 4: Breakthroughs in HER2-Amplified Colorectal Cancer

(20:48)

DESTINY-CRC02: trastuzumabe deruxtecano em pacientes com câncer colorretal metastático HER2+

(3:34)

DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer

(1:58)

Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC

(11:32)

Treatment optimisation in mCRC: third line and beyond

(31:13)

Dr. Strickler (Duke University Medical Center) discusses HER2 as an emerging target in mCRC patients

(1:3:3)

Updates from DESTINY-Gastric 01

(3:2)

Next-Generation Sequencing and Targets in Early-Phase Colorectal Cancer Drug Development

(16:21)

DESTINY-Breast01: a new “destiny” for HER2positive mBC patients?

(1:33)

Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology

(3:45)

ASCO 2023 Expert Report on novelties in the treatment of colorectal cancer by S. Stintzing

(9:55)

47. ASCO 2023 - Colorectal Cancer

(22:21)

DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

(4:41)

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

(2:40)

How can HER2-targeted therapies be incorporated into the management of patients with CRC?

(47:29)

Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01

(1:23)

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Ca...

(1:59)

HER2+ mBC: Study Design and Results of DESTINY-Breast01

(4:56)

Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer

(1:42)